JP2023518228A - 抗グリカン抗体及びそれらの使用 - Google Patents

抗グリカン抗体及びそれらの使用 Download PDF

Info

Publication number
JP2023518228A
JP2023518228A JP2022555661A JP2022555661A JP2023518228A JP 2023518228 A JP2023518228 A JP 2023518228A JP 2022555661 A JP2022555661 A JP 2022555661A JP 2022555661 A JP2022555661 A JP 2022555661A JP 2023518228 A JP2023518228 A JP 2023518228A
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
antigen
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518228A5 (https=
Inventor
レナード プレスタ，
トニー リャン，
ジェニファー チョン，
Original Assignee
ピーティーエム セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーエム セラピューティクス， インコーポレイテッド filed Critical ピーティーエム セラピューティクス， インコーポレイテッド
Publication of JP2023518228A publication Critical patent/JP2023518228A/ja
Publication of JP2023518228A5 publication Critical patent/JP2023518228A5/ja
Priority to JP2025176983A priority Critical patent/JP2026031937A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022555661A 2020-03-17 2021-03-16 抗グリカン抗体及びそれらの使用 Pending JP2023518228A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176983A JP2026031937A (ja) 2020-03-17 2025-10-21 抗グリカン抗体及びそれらの使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062990927P 2020-03-17 2020-03-17
US62/990,927 2020-03-17
US202063037374P 2020-06-10 2020-06-10
US63/037,374 2020-06-10
US202063074956P 2020-09-04 2020-09-04
US63/074,956 2020-09-04
PCT/US2021/022627 WO2021188591A1 (en) 2020-03-17 2021-03-16 Anti-glycan antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176983A Division JP2026031937A (ja) 2020-03-17 2025-10-21 抗グリカン抗体及びそれらの使用

Publications (2)

Publication Number Publication Date
JP2023518228A true JP2023518228A (ja) 2023-04-28
JP2023518228A5 JP2023518228A5 (https=) 2024-03-27

Family

ID=75581605

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555661A Pending JP2023518228A (ja) 2020-03-17 2021-03-16 抗グリカン抗体及びそれらの使用
JP2025176983A Pending JP2026031937A (ja) 2020-03-17 2025-10-21 抗グリカン抗体及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176983A Pending JP2026031937A (ja) 2020-03-17 2025-10-21 抗グリカン抗体及びそれらの使用

Country Status (8)

Country Link
US (3) US11230608B2 (https=)
EP (1) EP4121460A1 (https=)
JP (2) JP2023518228A (https=)
KR (1) KR20220155333A (https=)
CN (1) CN115698082A (https=)
AU (1) AU2021237566A1 (https=)
CA (1) CA3170434A1 (https=)
WO (1) WO2021188591A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023133452A1 (en) * 2022-01-06 2023-07-13 PTM Therapeutics, Inc. Methods of treating solid tumors and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JENNIFER C. BRAZIL ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 191, no. 9, JPN6025007966, 1 November 2013 (2013-11-01), pages 4804 - 4817, ISSN: 0005540686 *

Also Published As

Publication number Publication date
US20220340683A1 (en) 2022-10-27
US20210292432A1 (en) 2021-09-23
KR20220155333A (ko) 2022-11-22
WO2021188591A1 (en) 2021-09-23
AU2021237566A1 (en) 2022-09-29
CN115698082A (zh) 2023-02-03
CA3170434A1 (en) 2021-09-23
EP4121460A1 (en) 2023-01-25
US11230608B2 (en) 2022-01-25
US20250034276A1 (en) 2025-01-30
JP2026031937A (ja) 2026-02-25

Similar Documents

Publication Publication Date Title
JP6862435B2 (ja) 抗ｗｔ１／ｈｌａ特異的抗体
TWI862474B (zh) 結合至髓鞘寡樹突細胞糖蛋白質之抗體
JP7397445B2 (ja) Ｃｅｌｌ Ａｄｈｅｓｉｏｎ Ｍｏｌｅｃｕｌｅ３に結合する抗体
JP7784511B2 (ja) 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
JP7098854B2 (ja) 自己免疫疾患およびがんを治療するための抗ｃｘｃｌ１３抗体
JP2022104998A (ja) アミロイド沈着疾患を治療するための方法および組成物
CN114040925B (zh) 抗SIRPα单克隆抗体及其用途
TW202019477A (zh) BCMAxCD3抗體構建體之給藥方案
JP2024500920A (ja) 抗ｉｌ１ｒａｐ抗体
JP7397444B2 (ja) コンドロイチン硫酸プロテオグリカン－５に結合する抗体
JP2026031937A (ja) 抗グリカン抗体及びそれらの使用
TW202426498A (zh) Ccr8抗體之醫藥用途及給藥計劃
WO2020228604A1 (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
JP2023554557A (ja) 抗ｉｌ－４ｒ抗体又はその抗原結合断片の複合物及び医薬用途
TW202118784A (zh) 抗bcma藥劑之給藥方案
EP4004056B1 (en) Anti-lewis y antibodies and uses thereof in cancer therapy
US12006357B2 (en) Transthyretin antibodies and uses thereof
US20170137523A1 (en) Therapy for gist
WO2025042888A1 (en) Methods of treating digestive diseases and compositions thereof
RU2846776C1 (ru) Антитело против нектина-4, конъюгат, включающий его, и их применение
HK40098542A (zh) 抗SIRPα单克隆抗体及其用途
HK40094973A (zh) 抗SIRPα单克隆抗体及其用途
EA051551B1 (ru) Антитело против нектина-4, конъюгат, включающий его, и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260326

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421